Vaccination is one of the most important public health strategies to reduce mortality and morbidity of various infectious diseases. The COVID-19 pandemic was declared, on March 11, 2020, since then, the virus has spread rapidly, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have played the main substantial role in advancing the management of the COVID-19 pandemic. As is well known, sex/gender-related differences affect vaccine efficacy, response, and acceptability. This review aims to compare the effects of sexual dimorphism and gender-related differences factors on the efficacy, responses, and acceptance of the COVID-19 vaccines. As far as the COVID-19 vaccine effectiveness is concerned, both males and females with the COVID-19 vaccine showed consistent and impressive efficacy; although males showed slightly greater efficacy, there was no significant correlation between the efficacy of the COVID-19 vaccine and their sex or gender differences. Consequently, to reduce adverse reactions in females, sex differences should be considered in the design of the COVID-19 vaccine. It is also essential to conduct pragmatic trials to verify whether sex differences in vaccine response and efficacy vary with age.

Cardiovascular disease (CVD) is one of the leading causes of mortality and morbidity worldwide. Several studies highlighted the association of CVD with hyperuricemia. We searched PubMed, EMBASE, Scopus, and DOAJ with the following keywords, including hyperuricemia and cardiovascular disease, to address these topics: 1) mechanism of hyperuricemia 2) relationship of hyperuricemia with cardiovascular disease 3) Treatment of hyperuricemia

Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.